International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update.
Where this comes from
- Record sourced from PubMed, PMID 27134269.
- Also identified by DOI 10.3899/jrheum.160114.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Previous publications have described the International Dermatology Outcome Measures (IDEOM) group, comprising patients, physicians, health economists, participating pharmaceutical industry partners, payers, and regulatory agencies. The goal of IDEOM is to create patient-centered, validated measures of dermatologic disease progression and treatment efficacy for use in both clinical trials and clinical practice. We provide an update of IDEOM activities as of our 2015 IDEOM meeting in Washington, DC, USA.
Medical subject headings
- Arthritis, Psoriatic
- Dermatology
- Outcome Assessment, Health Care